AKESO(HK:09926) 智通财经网·2025-07-31 03:27Core Viewpoint - Kangfang Biopharma (09926) has seen a nearly 5% increase in early trading, reaching a historical high of 160.4 HKD, following the announcement of the initiation of a pivotal Phase III clinical trial for its innovative PD-1/VEGF bispecific antibody drug, Ivoris (brand name: Yidafang®) [1] Group 1: Clinical Development - The Phase III clinical study (AK112-305/HARMONi-8A) involves Ivoris in combination with Docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed prior PD-1/L1 inhibitors and platinum-based chemotherapy [1] - This marks the seventh Phase III study for Ivoris in the lung cancer field, with three of these being international multicenter registrations [1] - Ivoris has achieved comprehensive coverage of core indications in the NSCLC field and has established a multi-line treatment strategy, potentially reshaping the overall treatment landscape for advanced NSCLC globally [1] Group 2: Strategic Importance - Ivoris serves as the cornerstone drug for the company's "IO+ADC" 2.0 strategy, focusing on core immuno-oncology indications and has initiated a series of Phase III and Phase II clinical trials for first-line treatments [1]